Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Stephen D. Rubin"'
Autor:
Juliette Lambert, Cécile Pautas, Christine Terré, Emmanuel Raffoux, Pascal Turlure, Denis Caillot, Ollivier Legrand, Xavier Thomas, Claude Gardin, Karïn Gogat-Marchant, Stephen D. Rubin, Rebecca J. Benner, Pierre Bousset, Claude Preudhomme, Sylvie Chevret, Herve Dombret, Sylvie Castaigne
Publikováno v:
Haematologica, Vol 104, Iss 1 (2019)
The randomized, phase III ALFA-0701 trial showed that a reduced and fractionated dose of gemtuzumab ozogamicin added to standard front-line chemotherapy significantly improves event-free survival (EFS) in adults with de novo acute myeloid leukemia (A
Externí odkaz:
https://doaj.org/article/43cadb5fe3eb403d946e81a6eda975e0
Autor:
Charles Erlichman, Alex A. Adjei, Sumithra Mandrekar, Sara J. Felten, Roxanne C. Jewell, Robert J. Mullin, Tona M. Gilmer, Kevin M. Koch, Karen S. Flatten, Robert Friedman, Marina Gálvez-Peralta, Stephen D. Rubin, Joel M. Reid, Scott H. Kaufmann, Julian R. Molina
Supplementary Figures S1-S2 from Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e0e550a872ddce131c9f30edc3b3a58
https://doi.org/10.1158/1078-0432.22439653
https://doi.org/10.1158/1078-0432.22439653
Autor:
Eric P. Winer, Paolo Paoletti, Debasish Roychowdhury, Cristina Oliva, Denise Zembryki, Klaudia Steplewski, Bernie Dharan, Stephen D. Rubin, Joanne L. Blum, Adam Brufsky, Denise Yardley, Andrew Wardley, Stefania Gori, Sibylle Loibl, Eva Ciruelos, Richard Greil, Minetta C. Liu, Henri Roché, Hans-Joachim Stemmler, Christos Christodoulou, Dominique Lossignol, Devchand Paul, Véronique Diéras, Nancy U. Lin
Purpose: Brain metastases develop in one third of patients with advanced HER2+ breast cancer. Effective therapy for patients with central nervous system (CNS) progression after cranial radiation is extremely limited and represents a major clinical ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b28dc6c170e4838f473d40e9f1c8e4f
https://doi.org/10.1158/1078-0432.c.6517522
https://doi.org/10.1158/1078-0432.c.6517522
Autor:
Charles Erlichman, Alex A. Adjei, Sumithra Mandrekar, Sara J. Felten, Roxanne C. Jewell, Robert J. Mullin, Tona M. Gilmer, Kevin M. Koch, Karen S. Flatten, Robert Friedman, Marina Gálvez-Peralta, Stephen D. Rubin, Joel M. Reid, Scott H. Kaufmann, Julian R. Molina
Purpose: Topotecan resistance can result from drug efflux by P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) as well as survival signals initiated by epidermal growth factor receptor family members. The present studies were done to d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dca744d49960c0cf77b2b4de3860983
https://doi.org/10.1158/1078-0432.c.6517090
https://doi.org/10.1158/1078-0432.c.6517090
Autor:
Eric P. Winer, Paolo Paoletti, Debasish Roychowdhury, Cristina Oliva, Denise Zembryki, Klaudia Steplewski, Bernie Dharan, Stephen D. Rubin, Joanne L. Blum, Adam Brufsky, Denise Yardley, Andrew Wardley, Stefania Gori, Sibylle Loibl, Eva Ciruelos, Richard Greil, Minetta C. Liu, Henri Roché, Hans-Joachim Stemmler, Christos Christodoulou, Dominique Lossignol, Devchand Paul, Véronique Diéras, Nancy U. Lin
Supplementary Data from Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56d13815d0dc2df0ff0ad271f6254216
https://doi.org/10.1158/1078-0432.22440151.v1
https://doi.org/10.1158/1078-0432.22440151.v1
Autor:
Claude Preudhomme, Stephen D. Rubin, Emmanuel Raffoux, Sylvie Castaigne, Sylvie Chevret, Cécile Pautas, Xavier Thomas, Pascal Turlure, Pierre Bousset, Ollivier Legrand, Claude Gardin, Juliette Lambert, Rebecca J. Benner, Christine Terré, Hervé Dombret, Denis Caillot, Karïn Gogat-Marchant
Publikováno v:
Haematologica
Haematologica, Ferrata Storti Foundation, 2019, 104 (1), pp.113-119. ⟨10.3324/haematol.2018.188888⟩
www.haematologica.org/content/104/1/113
Haematologica, 2019, 104 (1), pp.113-119. ⟨10.3324/haematol.2018.188888⟩
Haematologica, Ferrata Storti Foundation, 2019, 104 (1), pp.113-119. ⟨10.3324/haematol.2018.188888⟩
www.haematologica.org/content/104/1/113
Haematologica, 2019, 104 (1), pp.113-119. ⟨10.3324/haematol.2018.188888⟩
The randomized, phase III ALFA-0701 trial showed that a reduced and fractionated dose of gemtuzumab ozogamicin added to standard front-line chemotherapy significantly improves event-free survival (EFS) in adults with de novo acute myeloid leukemia (A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cb677892e09102942f378e3e9613adb
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01984959
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01984959
Autor:
Juliette, Lambert, Cécile, Pautas, Christine, Terré, Emmanuel, Raffoux, Pascal, Turlure, Denis, Caillot, Ollivier, Legrand, Xavier, Thomas, Claude, Gardin, Karïn, Gogat-Marchant, Stephen D, Rubin, Rebecca J, Benner, Pierre, Bousset, Claude, Preudhomme, Sylvie, Chevret, Herve, Dombret, Sylvie, Castaigne
Publikováno v:
Haematologica
The randomized, phase III ALFA-0701 trial showed that a reduced and fractionated dose of gemtuzumab ozogamicin added to standard front-line chemotherapy significantly improves event-free survival (EFS) in adults with de novo acute myeloid leukemia (A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8a570455396af728ca5e6c37b2732b89
https://pubmed.ncbi.nlm.nih.gov/30076173
https://pubmed.ncbi.nlm.nih.gov/30076173
Autor:
Maureen E. Trudeau, Massimo Cristofanilli, Zhimin Shao, Kimberly L. Blackwell, Ricardo H. Alvarez, Sufia Safina, Stephen D. Rubin, Suman Redhu, Alexey Manikhas, Oleg Gladkov, Sulabha Ranganathan, Stephen R. D. Johnston, Henry L. Gomez
Publikováno v:
Breast Cancer Research and Treatment
This multi-center Phase II study evaluated lapatinib, pazopanib, and the combination in patients with relapsed HER2+ inflammatory breast cancer. In Cohort 1, 76 patients were randomized 1:1 to receive lapatinib 1,500 mg + placebo or lapatinib 1,500 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baa4e564e4b3d38ad350d2cb2d65147f
https://doi.org/10.1007/s10549-012-2369-x
https://doi.org/10.1007/s10549-012-2369-x
Autor:
Stephen D. Rubin, Vinay Rudraraju, Kunal S Taskar, Emily Hua, Diane Palmieri, Ramakrishna Samala, Brunilde Gril, Stephen Castellino, Paul R. Lockman, Julie A. Lockman, Patricia S. Steeg, Quentin R. Smith, Joseph W. Polli, Helen R. Thorsheim, Rajendar K. Mittapalli
Publikováno v:
Pharmaceutical Research. 29:770-781
Lapatinib, a small molecule EGFR/HER2 inhibitor, partially inhibits the outgrowth of HER2+ brain metastases in preclinical models and in a subset of CNS lesions in clinical trials of HER2+ breast cancer. We investigated the ability of lapatinib to re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25824a92d409184c9f6c6b601b2f2857
https://doi.org/10.1007/s11095-011-0601-8
https://doi.org/10.1007/s11095-011-0601-8
Autor:
Debasish F. Roychowdhury, Henri Roché, Hans-Joachim Stemmler, Cristina Oliva, Joanne L. Blum, Paolo Paoletti, Minetta C. Liu, Richard Greil, Devchand Paul, Dominique Lossignol, Denise A. Yardley, Denise Zembryki, Eric P. Winer, Sibylle Loibl, Nan Lin, Christos Christodoulou, Stephen D. Rubin, Eva Ciruelos, Bernie Dharan, Stefania Gori, Andrew M Wardley, Klaudia Steplewski, Adam Brufsky, Véronique Diéras
Publikováno v:
Clinical Cancer Research. 15:1452-1459
Purpose: Brain metastases develop in one third of patients with advanced HER2+ breast cancer. Effective therapy for patients with central nervous system (CNS) progression after cranial radiation is extremely limited and represents a major clinical ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3640e97ec8c0d3be765c0aa7b751d1ca
https://doi.org/10.1158/1078-0432.ccr-08-1080
https://doi.org/10.1158/1078-0432.ccr-08-1080